MedTrace Logo

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

NCT01280695 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2014-04-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

Placebo Capsules

DRUG

MSDC-0602 100 mg

MSDC-0602 100 mg Capsules

DRUG

MSDC-0602 250 mg

MSDC-0602 250 mg Capsules

DRUG

MSDC-0602 250 mg

MSDC-0602 500 mg Capsules

DRUG

Pioglitazone

Pioglitazone 45 mg Capsules

Sponsors & Collaborators

  • Metabolic Solutions Development Company

    lead INDUSTRY

Principal Investigators

  • Jerry Colca, PhD · Metabolic Solutions Development Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01280695 on ClinicalTrials.gov